Dupilumab Effectively Controls Severe Atopic Dermatitis: Study Finds
A recent longitudinal cohort study found that dupilumab provides sustained, 12-month disease control for severe atopic dermatitis, with 85.2% of patients reaching objective clinical targets and 83.6% achieving patient-perceived symptom control, as published in the Indian Journal of Dermatology in May 2026.
Atopic dermatitis (AD) imposes significant physical and economic burdens, yet patient perspectives are often underrepresented in clinical efficacy data. To address this clinical gap, Andrea Miniello and colleagues from the Department of Emergency and Organ Transplantation at the University of Bari Aldo Moro conducted a 12-month longitudinal investigation evaluating long-term outcomes through an integrated assessment of clinical signs and patient-reported outcome measures (PROMs).
Therefore, the single-center retrospective cohort study evaluated 61 patients with severe AD (baseline EASI ≥24) treated with standard subcutaneous dupilumab for 52 weeks. Outcomes were analyzed at 16 and 52 weeks using Generalized Estimating Equation models, excluding patients with incomplete data or treatment interruptions to ensure a rigorous assessment of symptom severity and quality of life.
Key clinical findings from the study include:
Progressive Patient-Perceived Control: The study reported that the proportion of patients achieving adequate disease control, measured by an Atopic Dermatitis Control Tool score below seven, surged from 50.8% at four months to a remarkable 83.6% by the end of the year.
Significant Clinical Clearance: Objective physician assessments revealed a substantial therapeutic trajectory, with the percentage of patients reaching an Eczema Area and Severity Index of seven or less increasing from 59% at the first follow-up to 85.2% at 12 months.
Rapid Relief from Pruritus and Sleep Loss: Patient-reported relief was nearly universal by one year, as 88.5% achieved minimal itch intensity and 91.8% reported successfully controlled sleep disturbances.
Enhanced Life Quality: The research highlighted a significant impact on daily well-being, with 86.9% of the cohort meeting the treat-to-target threshold for the Dermatology Life Quality Index by the study's conclusion.
Favorable Safety Profile: While 21.3% of participants experienced mild treatment-related conjunctivitis, these events did not necessitate the discontinuation of therapy, reinforcing the drug’s long-term tolerability.
The results suggest that long-term dupilumab administration leads to consistent and statistically significant improvements across all measured outcomes, with the vast majority of patients achieving stable disease control between the four-month and twelve-month intervals.
These findings imply that the integration of the Atopic Dermatitis Control Tool into regular clinical practice could provide a more holistic understanding of a patient’s response to biological therapy beyond traditional surface-level skin assessments.
While the documented success is encouraging, the retrospective design and the potential for positive bias from patients who remained on therapy suggest that larger, prospective studies utilizing individual item analysis are needed to further validate these long-term control patterns.
Reference
Miniello A, Pugliese F, Pepe I, Pastore G, Lassandro M, Calabrese C, et al. Evaluation of outcomes of dupilumab therapy in patients with atopic dermatitis – A single-center retrospective longitudinal study. Indian J Dermatol 2026;71:185-90..
